Emotra develops products in the field of psychiatry and psychology with the goal of providing treating physicians with more and better information. The company's product, EDOR, is a psychophysiological test that identifies hyporeactive patients. Hyporeactivity among depressed patients functions as a biomarker describing a condition with greater risks, including for relapse in depression. Customers consist of specialist psychiatric clinics, university hospitals and research institutes. The company has its office at AstraZeneca BioVentureHub in Mölndal.